Targovax announces poster at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Targovax announces poster at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

PR Newswire

OSLO, Norway, Nov. 9, 2020

OSLO, Norway, Nov. 9, 2020 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today announces that the poster "A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma - 12-month analysis of biomarkers and clinical outcomes" are now available at the Company's website.

The abstract presents the 12-month analysis of biomarkers and clinical outcome from the phase I/II trial in malignant pleural mesothelioma where ONCOS-102 is added to standard of care chemotherapy (pemetrexed / cisplatin). This analysis supports the data presented in June.

                                   

                                   

Title (361):

                                   

A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma - 12-month analysis of biomarkers and clinical outcomes

                                               

                                   

                                   

Presenter:

                                   

                                   

                                   

Prof. Luis Paz-Ares, Principal Investigator of the trial and Chair of the Medical Oncology Department at the Hospital Doce de Octubre, Madrid

                                   

                                               

                                   

                                   

Poster session:

                                                                       

Location:

                                   

                                   

                                   

Wednesday 11. November 23:15-23:45 CET (17:15-17:45 EST)

                                   

Friday 13. November 22:40-23:10 CET (16:40-17:10 EST)

                                   

Virtual Poster Hall

                                   

                                   

The poster is also available on Targovax's website.

About SITC Annual Meeting 2020

The Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020) will be reimagined as a fully VIRTUAL experience this year to ensure the health and safety of program attendees and their patients.SITC 2020 provides a multidisciplinary educational and interactive environment focused on improving cancer patient outcomes by incorporating strategies based on basic and applied cancer immunotherapy.

CONTACT:

For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

IR enquires:
Kim Sutton Golodetz - LHA Investor Relations (US)
Email: kgolodetz@lhai.com
Phone: +1 212-838-3777

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/targovax/r/targovax-announces-poster-at-the-2020-society-for-immunotherapy-of-cancer--sitc--annual-meeting,c3233804

Voltar noticias em Inglês